Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMAHA-003 in metastatic castration-resistant prostate cancer
CTR20240625Phase 3Active
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of opevesostat in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Merck & Co.. Started May 2024; status: active.
02
Drugs
opevesostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20240625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240625.